ACET Adicet Bio, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1720580 · Fiscal year ends 12/26
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY20.9%
TTM EPS YoY78.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-85.9%
ROA-67.5%
ROIC (approx.)-97.0%
Asset turnover—
Leverage & solvency
Liabilities / assets20.4%
Debt / equity0.00x
Current ratio6.09x
Interest coverage-1,038.62x
Cash quality & payout
Operating cash flow / net income0.88x
Accruals ratio-8.1%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $99.13M | $99.32M | $106.04M | $71.25M | $48.94M |
| SG&A expense | $22.99M | $28.29M | $26.53M | $26.30M | $22.22M |
| Operating income | -$122.11M | -$127.61M | -$152.04M | -$72.55M | -$61.43M |
| Interest expense | $36,000 | $4,000 | $25,000 | $80,000 | $176,000 |
| Pretax income | -$116.80M | -$117.12M | -$142.66M | -$69.79M | -$62.12M |
| Income tax | $0 | $0 | $0 | $0 | -$125,000 |
| Net income | -$116.80M | -$117.12M | -$142.66M | -$69.79M | -$62.00M |
| EBITDA | -$115.73M | -$121.15M | -$145.94M | -$69.98M | -$59.90M |
| EPS (basic) | -16.95 | -21.33 | -3.31 | -1.70 | -2.00 |
| EPS (diluted) | -16.95 | -21.33 | -3.31 | -1.70 | -2.00 |
| Weighted avg. shares (diluted) | 6.89M | 5.49M | 43.04M | 41.08M | 30.95M |
| Balance sheet | |||||
| Cash & equivalents | $38.92M | $59.40M | $159.71M | $257.66M | $277.69M |
| Short-term investments | — | — | $0 | — | $0 |
| Current assets | $160.93M | $180.14M | $162.27M | $261.04M | $282.44M |
| PP&E, net | $16.53M | $22.52M | $26.78M | $28.71M | $14.64M |
| Goodwill | — | — | $0 | $19.46M | $19.46M |
| Intangibles | — | — | — | — | $0 |
| Total assets | $192.35M | $220.22M | $207.29M | $330.69M | $338.94M |
| Current liabilities | $21.53M | $19.39M | $19.29M | $19.71M | $16.32M |
| Total liabilities | $33.15M | $33.61M | $37.12M | $38.35M | $35.81M |
| Shareholders' equity | $159.21M | $186.61M | $170.18M | $292.34M | $303.13M |
| Shares outstanding | 9.59M | 5.16M | 43.27M | 42.95M | 39.74M |
| Cash flow statement | |||||
| Operating cash flow | -$95.25M | -$92.38M | -$93.72M | -$44.77M | -$51.05M |
| Capital expenditure | $1.74M | $1.12M | $4.46M | $16.78M | $13.05M |
| Free cash flow | -$96.98M | -$93.50M | -$98.18M | -$61.55M | -$64.10M |
| Investing cash flow | $2.39M | -$119.24M | -$4.46M | -$16.78M | -$2.80M |
| Financing cash flow | $75.25M | $111.31M | $236,000 | $41.51M | $242.69M |
| Depreciation & amortization | $6.38M | $6.47M | $6.10M | $2.58M | $1.54M |
| Stock-based compensation | $14.27M | $22.23M | $20.26M | $17.13M | $12.51M |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.